NSE close · Mon, 28 SeptNifty 5022,780.25▼ 1.56%Nifty Bank54,471.65▼ 1.99%Midcap 10059,914.20▼ 1.63%Smallcap 25017,863.20▼ 1.63%India VIX13.64▲ 12.17%IT28,086.50▼ 0.26%Auto26,525.05▼ 1.64%Pharma26,761.65▼ 0.89%FMCG45,264.35▼ 1.47%Metal12,854.40▼ 1.78%Realty850.90▼ 2.12%Energy36,693.20▼ 2.00%PSU Bank8,026.10▼ 3.24%Financials24,671.65▼ 1.69%Media1,539.25▼ 0.74%Defence9,231.20▼ 1.81%Durables38,162.90▼ 0.30%Biggest movesRSYSTEMS▲ 16.8%REPRO▲ 15.8%DAMCAPITAL▲ 14.8%SMCGLOBAL▲ 13.6%BPLPHARMA▲ 13.3%PRIMO▲ 11.3%SSDL▲ 11.2%SYNCOMF▲ 10.7%

Top stories

Broker call + Lerodalcibep · 1 storyClear filters

Developing 156 Picking up 25 Price moves 60 Following

Busiest tags today

Market valuations143 Global markets143 AI140 Crude oil139 Nifty and Sensex105 Geopolitics104 Bond yields81 Iran78 Banks71 US Treasuries56 Trade and tariffs55 Gold53 Wall Street48 Listing rules44 Every tag in Market pulse →

Topic

Lerodalcibep▲ +100% net tone today

2 stories today · 2 since 28 SeptSun Pharma −0.8% on Mon, 28 Sept

Often with, this weekPharma and healthcare2 Sun Pharma2 China1

Open tag page →Clear ×

Stories per day

128 Sept

129 Sept

Broker call▲

Sun Pharma Lerodalcibep Deal: Macquarie Sees Cross-Selling Opportunities, Maintains 'Outperform' Call

Sun Pharma will pursue regulatory approvals in licensed territories where approval has not yet been obtained
Regulatory progress may shape Sun Pharma’s licensed-market opportunities

Sun Pharma Lerodalcibep Pharma and healthcare1 source · 51m

That’s everything for today